- Home
- CWEN vs LEGN Comparison
CWEN vs LEGN Comparison
Compare CWEN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | LEGN |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CWEN | LEGN |
|---|---|---|
| Price | $31.76 | $19.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $42.00 | ★ $61.33 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | ★ 11.94 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $1,429,000,000.00 | N/A |
| Revenue This Year | $16.38 | $42.68 |
| Revenue Next Year | $8.48 | $30.52 |
| P/E Ratio | $43.20 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $27.67 | $16.24 |
| 52 Week High | $41.74 | $37.50 |
Technical Indicators
Market Signals| Indicator | CWEN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 41.55 |
| Support Level | $30.19 | $17.01 |
| Resistance Level | $34.12 | $23.66 |
| Average True Range (ATR) | 0.87 | 1.02 |
| MACD | -0.06 | 0.18 |
| Stochastic Oscillator | 8.18 | 7.41 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.